Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Giovanni
Also all the fing terrible side effects of the spike proteins!!
Giovanni
News alert.
Mnra shot is of questionable efficacy against the Chinese virus.
Then you post the proof. You aren’t helping your case or his by just saying “ya it’s out there, trust me”. Do you realize if there was a death and multiple icu admissions in the placebo group this trial would have been stopped a long time ago ? No way would they not halt the trial with those results.
Think about those suckers who bought the offering only to watch there investment drop 50% in days
Meanwhile MF is playing golf in the Bahamas???
Connect the dots peeps
He’s not hiding anything it’s all in plain sight unfortunately
Sheep will be sheep
Thank you for the update.
Agreed, unblinded the final 500 is the keys to our success.
Just because you have not seen it
does not mean
he is making that up.
Get up to speed:0)))
Also that trial was not a Fda trial....could that be a big part of the reason why they are asking for more clinical data before evaluating it? that's what I'm thinking, maybe I'm wrong lol.
But maybe why this one is fairly new. Other names for Ensitrelvir,S-217622
https://en.wikipedia.org/wiki/Ensitrelvir
Trial I'm talking about here, Actual Study Start Date : December 23, 2022
Estimated Study Completion Date : March 1, 2024
https://clinicaltrials.gov/ct2/show/NCT05605093?term=NCT05605093&draw=2&rank=1
So now your in the same camp as me???
I agree this is going to .02
“To those who have totally lost ALL confidence in the company..........by all means SELL since 5c or lower will be most welcome!!!”
What year was mRNA invented?
We can be sure that neither François Gros nor François Jacob could have imagined back in 1961 that, 60 years later, this highly unstable messenger RNA could be used to produce vaccines that are now being administered to the world's population to protect them against COVID-19.
Discovery of messenger RNA in 1961 - Institut Pasteur
pasteur.fr
https://www.pasteur.fr › home › research-journal › news
-------------
Spike proteins are hurting tiny numbers maybe!
Delaying what seems to be a proven Japanese option till late ‘24. Similar to delaying a Canadian startup…FDA gonna FDA
Pb I seen this few weeks ago also..
But today Shionogi revealed they don't expect FDA approval until late 2024
Confirms FDA is requiring more clinical data before evaluating it
Ensitrelvir should be approved already, being as effective as Paxlovid, but with fewer drug-drug interactions
— Michael Lin, MD PhD 🧬 (@michaelzlin) February 27, 2023
But today Shionogi revealed they don't expect FDA approval until late 2024
Confirms FDA is requiring more clinical data before evaluating ithttps://t.co/C38I7k7fCL
What a shameful example of probably extremely poor treatment with no therapeutics early during the onstage of the China virus into her body. Maybe exacerbated by the the spike proteins in the experimental shots and boosters she was given. God bless her!
That is public information.
If you do a little DD you will find it.
Enjoy the day.
I read your article. So it appears that a specific trial is going to have to be done to determine if Bucillamine works for long haulers. It's not enough to just go back and ask each person about symptoms now, It has to be in the design. With fewer people getting covid, patients are going to be hard to find. I still believe in this stock although this has clearly gone on too long for us to make what we originally anticipated. Cheers to unblinded the final 500 and show the world that this drug is boss for many infectious diseases including covid. I hope I am wrong about long haulers. Unblinding and a buyout will still be a nice return.
You going to show us where you got the information about the 1 death and multiple icu admissions in the placebo group?
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
It took 6 months to answer some questions and put together some data that they already have so lord knows how long this next submission will take
Eco
I knew all.that of course. I wanted to hear it again at this time for any newbies
And we wait for another five years. Hope that's not the case, but it sure looks that the direction we're going. Five f years. Does anyone know how long to get that data out to FDA as they requested?
And we wait for another five years. Hope that's not the case, but it sure looks that the direction we're going. Five f years. Does anyone know how long to get that data out to FDA as they requested?
Vision Problems After COVID: Causes and Treatment
EDUCATION & RESOURCES | COVID
Share:
When most people think of COVID-19 symptoms, they often recall the most common acute symptoms: brain fog, sore throat, congestion, headaches, and the like. What many don’t know is that long COVID can affect your vision for months after contracting the illness.
Current studies show that 1 in 10 COVID patients experience at least one eye problem, such as dryness, redness, blurred vision, or sensitivity to light. Conjunctivitis is common in the early stages of the illness, and for some patients, it’s the first sign of a COVID-19 infection.
However, as we’ll discuss in this article, the real number of patients experiencing eye issues is likely higher, and the range of symptoms is much broader. Red and watery eyes are easy to spot, but it can be challenging for patients to recognize symptoms that stem from gaze and focus abnormalities. Some examples of potentially vision-related symptoms are headaches, difficulty focusing while reading, feeling overwhelmed in crowded spaces, dizziness while in a moving vehicle, and more. Because most research studies (a) rely on asking patients about their symptoms and (b) don’t include all of the appropriate tests to diagnose vision problems, many post-COVID vision changes go unreported.
We also know that COVID patients don’t just experience vision problems. They also have a wide range of symptoms, from cognitive issues to digestive problems. The best approach to recovery for these patients is one that considers the whole person. It’s key that post-COVID patients find a provider who can address the wide range of effects long COVID has throughout the body and who is willing to diagnose the root issue (rather than treating just symptoms).
At Cognitive FX, we look at how the virus has affected your brain and body, then devise a plan to restore normal function. Our approach involves a combination of aerobic exercise and multidisciplinary therapies to address specific issues that you’re experiencing, including problems with your vision if you have them.
In this article, we’ll look at:
Misconceptions about COVID-19 and vision symptoms
Vision symptoms caused by COVID-19
How COVID can cause vision problems
Treatment for long COVID at Cognitive FX
Tips for alleviating vision symptoms
Our treatment was originally designed to help post-concussion patients recover from persistent symptoms. After just one week of treatment, over 90% of our patients show improvement. Thus far, we’ve seen similar results with long COVID patients who pass our current screening criteria. To discuss your specific symptoms of COVID-19 and determine whether you’re eligible for treatment at our clinic, schedule a consultation.
Can COVID-19 Cause Vision Problems?
A doctor checks a women's vision.
Soon after the coronavirus pandemic started in 2020, ophthalmologists worldwide started reporting how patients infected with the virus were experiencing visual symptoms during their illness. Common symptoms identified during these early stages included conjunctivitis, dry and itchy eyes, blurry vision, and sensitivity to light.
However, over the past two years, the medical community and ophthalmology experts spotted a wider range of symptoms than previously expected, such as issues with saccades (how your eye switches focus from point to point), control of eye movements, and communication issues between the vestibular and visual systems. These issues are difficult for patients themselves to recognize and many doctors are not trained to look for and diagnose them. As a result, there are some misconceptions about the impact of COVID-19 on vision.
When you think of problems with vision, you might think of people who need to wear glasses. Some see well at a distance but need glasses to see images that are near (hyperopia), while others can see objects that are near clearly but need glasses to see distant objects (myopia). Someone with 20/20 vision can see both near and far objects clearly and thus does not need glasses.
However, it’s possible to have vision-related changes triggered by COVID-19 and to still have 20/20 vision. Many vision problems don’t affect visual acuity. Patients' eyes may not converge or diverge correctly. They might struggle with certain types of eye movement, experience reduced peripheral vision, not see clearly when they’re moving… the list of possible problems with your eyes is quite long.
This brings us to our first misconception: Many patients believe that just because they haven’t noticed any problems with their vision that their eyes and visual system are functioning normally. In reality, it can be quite difficult to detect problems in your own vision because your brain does its best to compensate.
Instead of noticing your eye problems, you’re more likely to experience the symptoms those eye problems result in: headaches, dizziness, nausea, difficulty concentrating, fatigue, and more. Most people are not aware of how the visual system can cause these symptoms, and they never think to seek help from a vision specialist.
A second misconception is that vision problems caused by COVID-19 are rare. This is somewhat supported by clinical studies. Studies over the past two years found ocular manifestations in patients with COVID-19 ranging from 2% to 32%, with most results hovering around 10%.
However, we believe the real value is much higher. Most of these studies only followed participants for a few weeks and looked for obvious symptoms like red and itchy eyes, which are easy to detect. Symptoms like problems with divergence (the ability to focus on a distant object) and convergence (the ability to focus on a close object) require specialized tests.
In addition, symptoms may not develop immediately and might come and go in waves like many other long COVID symptoms. To get a more accurate understanding of the situation, we need clinical studies which follow patients for more extended periods and which test for a wider range of symptoms.
Vision Symptoms Caused by COVID-19
Learn what vision symptoms can be caused by COVID and which one's are typically caused by other factors.
One of the most commonly reported eye conditions caused by COVID-19 in both children and adults is conjunctivitis (colloquially called pink eye). Some studies found that 9 in 10 patients with eye symptoms experience this condition. These patients often experience red and itchy eyes, dry eyes, watery eye discharge, sensitivity to light, and eye pain. In some cases, this eye condition may also cause blurry vision and swollen eyes.
In addition to conjunctivitis, vision symptoms caused by COVID-19 may include the following:
Ocular irritation
Red eyes
Eye soreness
Blurry vision
Tunnel vision
Double vision
Vision loss
Floaters in the eyes
Cotton wool spots
Loss of peripheral vision
Uveitis (inflammation of the eye)
Eye infection
Swollen eyelids
Sensitivity to light
Glaucoma
Divergent and convergent issues
Saccades problems
Gaze fixation issues
Problems with focus
Vestibular-ocular deficiencies
Retinal artery occlusion and retinal vein occlusion caused by hemorrhage or blood clots
Causes of Vision Problems After COVID-19
Learn possible long-lasting effects of COVID on your vision.
There are many possible ways to explain how COVID-19 can cause vision problems. For most patients, it’s likely a mixture of multiple factors. Some of the most important reasons include…
Disruption of the Autonomic Nervous System (ANS)
Neurovascular Coupling (NVC) dysfunction
Direct impact on brain function related to vision
Vestibular issues
Pre-existing visual dysfunction
Side effects of medication
Blood clots
Direct viral attack on the eyes
Ventilators
Disruption of the Autonomic Nervous System (ANS)
We’ve discussed in a previous post how COVID-19 can disrupt the normal functioning of the autonomic nervous system (ANS).
Along with other important functions like controlling heart rate and blood pressure, this part of the nervous system is also involved in vision. Specifically, it controls the movement of the iris to fine-tune the amount of light that enters the eye, similar to a camera aperture.
The ANS has two important components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS). Stimulation of the sympathetic branch, which triggers "fight or flight" responses when the body is under stress, induces pupil dilation. In contrast, stimulation of the parasympathetic system, known for "rest and digest" functions, causes the pupil to contract.
Under normal circumstances, SNS and PNS work in balance, and the size of the pupils change as needed. In COVID patients, however, the SNS tends to be dominant, which may cause some vision issues, such as light sensitivity and blurry vision.
Neurovascular Coupling (NVC) Dysfunction
Vision problems can also occur if there’s a disruption in the way nerve cells receive the resources they need to function normally. Under normal circumstances, brain cells get nutrients and oxygen from a network of blood vessels. The dynamic relationship between blood vessels and the particular neuronal clusters they supply with resources is called neurovascular coupling (NVC).
If this dynamic relationship is disrupted, affected regions of the brain may struggle to perform regular functions. Researchers have already established that COVID-19 can have a long-term impact on the brain. Recently, a study found damage in multiple brain regions over four months in elderly adults after they experienced a COVID infection. If you want to find out more, we have written about this important study in more detail in another post.
It’s not unreasonable to think that if the virus affects function in the visual cortex — the primary region of the brain that receives and processes visual information — it can lead to vision problems such as poor visual acuity, loss of field of vision, and sensitivity to light.
If you notice that your vision gets worse during or after highly demanding cognitive tasks, it’s likely that you’re experiencing symptoms caused by NVC dysfunction. It’s also not unusual for the effects of NVC dysfunction to combine with ANS dysfunction.
Vestibular Issues
Many COVID-19 patients also experience symptoms affecting the vestibular system, including dizziness, balance problems, and vertigo. A common complaint for these patients is that their vision is also affected. They can have problems focusing on objects or “seeing” objects moving from side to side. (There are evolving hypotheses linking COVID’s effect on the brainstem to these symptoms.)
This occurs because the vestibular system communicates with the eyes via an automatic function called the vestibulo-ocular reflex (VOR). The VOR is crucial to maintaining both balance and clear vision, controlling the position of the eyes so that when you move, you can keep your gaze stable and fixed on a certain point. However, if this system is not working properly due to a Sars-CoV-2 infection, patients may experience blurry or double vision, even though there’s nothing wrong specifically with the eyes.
A young man demonstrates how to use a Brock string.
Pre-existing Visual Dysfunction
Some patients have vision problems they aren’t aware of which are then exacerbated by COVID-19. The brain does an amazing job of compensating for small problems in eye coordination and other visual issues. But if your brain is affected by COVID-19, it may not have enough bandwidth to compensate for those issues any longer. The result is a seemingly new set of vision problems when in reality, they just weren’t bad enough to cause symptoms until now.
Side-effects of Medication
Some commonly prescribed drugs can have adverse ocular effects. Some of these go away when the patient stops taking the medication, but others may cause irreversible vision loss.
This is particularly dangerous for COVID patients with diabetes, heart disease, and hypertension. For example, some medications for hypertension and diabetes cause abnormalities in pupil size, while some drugs for heart disease increase the risk of cataracts and cause eye irritation. The list of medications with a potential impact on vision includes steroids, antihistamines, antipsychotics, and any meds that affect blood flow. (Some research shows a large increase in the incidence of macular degeneration linked to blood pressure medication).
In addition, some antiviral medications can cause mild eye inflammation and redness, as well as blurry vision and ocular pain. However, there is no evidence that meds routinely used to treat most COVID-19 patients can cause vision problems.
Our advice is to contact your physician or eye doctor if you experience any visual symptoms. Most symptoms are only mild, and you may feel that these problems are a reasonable trade-off for a potentially life-saving drug. Make sure you inform your doctor of all the medications you take, including prescription and over-the-counter, along with the dosages.
Other Possible Causes
Poor blood flow to the retina and cornea: Blurred vision can result from the virus blocking, or at least restricting, the blood supply to the eye. This is known as retinopathy. Without nutrients and oxygen, the tissue in the retina may start to swell and die, making this area look white and fluffy, like cotton wool. These are commonly known as cotton wool spots and do not typically affect a person's visual acuity, but may cause eye pain.
Direct viral attack: The virus may be able to get into the body through the eyes. If SARS-CoV-2 reaches the surface of the eye, it can travel through the mucous membrane and eventually reach the retina all the way in the back of the eye. Expression of the ACE-2 receptor allows the virus to infect cells in the eye, which may explain many symptoms such as conjunctivitis, red and itchy eyes, and blurry vision. Given the connection between the eye and brain via the optic nerve, infection of the retina could be a way for the virus to reach the brain and cause further damage.
Ventilators: It’s possible that COVID patients who suffered a severe COVID-19 infection develop vision problems after being on a ventilator. A study suggested that some patients on ventilators have nodules growing on the macula of the eye (this macular part processes what’s directly in front of the eyes), increasing the risk of conjunctivitis, vascular problems, and potential loss of vision.
Treatment at Cognitive FX
Treatment at Cognitive FX includes a variety of activities.
Most long COVID patients who experience vision problems and eye disease also have a wide range of other symptoms, such as brain fog, difficulty sleeping, and headaches, to name just a few. Instead of looking at visual issues in isolation, our approach is to tackle the root of the problem and address multiple symptoms at the same time.
Before treatment, you will undergo a detailed medical examination, allowing our doctors to find out more about your medical history and current symptoms. Part of our evaluation includes a functional Neurocognitive Imaging scan (fNCI) to identify which regions of the brain were affected by neurovascular coupling dysfunction and how well they’re communicating with other brain regions. The scan includes 56 areas of the brain. Using the information from the scan and the medical examination, our team will design a treatment plan custom-made for your needs.
For example, this part of an fNCI report shows regions involved in reading comprehension, whether they are hypoactive (indicated a blue color on the report), and whether they’re communicating with each other as expected:
Vision Problems After COVID Causes and Treatment (2)-1
During our week-long treatment — called Enhanced Performance in Cognition, or EPIC for short— patients receive multidisciplinary therapy, including…
Vision therapy
Neuromuscular therapy
Occupational therapy
Vestibular therapy
Cognitive therapy
Sensorimotor therapy
Neurointegration therapy
Psychotherapy
And more.
These therapies are appropriate therapeutic approaches for NVC dysfunction, autonomic dysfunction, vision problems, and vestibular issues. Some of the post-COVID symptoms these therapies can help resolve in addition to vision include…
Respiratory symptoms
Persistent fatigue
Short-term memory problems
Headaches
Brain fog
And more.
All of our therapies have a visual component and will address some of your symptoms. However, we also have specific activities to rehabilitate your vision, such as the Brock string and Dynavision.
Therapists demonstrate how to use a Brock string.
Our therapists use the Brock string for patients who are experiencing visual perception issues. This tool helps retrain the eyes to work together to focus on beads located at different distances along the string.
Dynavision is a computerized light board where patients push buttons as they light up, following different patterns on the board. The task may be as simple as hitting every button that lights up as quickly as possible, or it may be more challenging, where you only hit the green and avoid the red lights. This is a great tool to improve oculomotor coordination and for activating a number of brain regions involved in movement, cognition, and vision.
Therapist demonstrates how to use Dynavision board.
Many of our patients experience significant improvements in just one week in many of their symptoms, but vision problems often need more than one week’s worth of therapy. It may take from six months to a year of vision therapy for your eyes to fully recover. We can refer you to a vision specialist in your hometown and show you how to do specific exercises at home.
Our patients report a significant decrease in symptoms related to emotional function, sleep, concentration, clarity of thought, memory, and light sensitivity at the end of one week of treatment.
While many other symptoms show direct improvement, they often require some rest at home or continuing therapy for a more marked improvement. Many patients are understandably tired after an intense week-long treatment protocol and experience less fatigue when they’re able to rest at home.
Vision Problems After COVID Causes and Treatment (3)-2Percent symptom decrease based on 43 patient evaluations.
At the end of the week, you will receive a second fNCI scan to see how your brain is improving. Then, our clinicians will analyze your results and give you some homework, which typically includes aerobic exercise, cognitive games, and cognitive rest to help you continue your recovery journey at home.
Tips to Help You Cope With Vision Symptoms at Home
Not surprisingly, COVID long haulers with visual symptoms can experience difficulties with many activities during the day, including cooking, shopping, watching television, and reading. Here are a few tips to improve eye health and cope with your symptoms at home and work:
Follow the 20-20-20 rule: If your work involves long periods of the day in front of a computer or any other activities that rely heavily on your vision, you might suffer from mental fatigue, dry eyes, and headaches. Throughout the day, take a 20-second break away from the computer every 20 minutes and focus on an object about 20 feet away from you. This is a quick and easy exercise to reduce eye strain. Also, limit screen time as much as possible.
Palming to relax your eyes: Cup your hands and apply gentle pressure over the sockets of your eyes for about 30 seconds. Close your eyes and breathe deeply. You can repeat this exercise throughout the day to relax your eyes. For your eye care routine, you may also find it helpful to apply eye drops (but avoid overuse).
Make a conscious effort to blink more during the day. This lubricates your eyes and helps your brain to process new visual data more efficiently.
Be strategic with lights. Make sure lighting in your home is sufficiently bright to see, but not so bright that it increases headaches. Use blue filters on electronic devices such as phones and tablets. You can also purchase screens specifically designed to reduce eye strain, but these can be expensive.
Reduce tripping hazards. Always keep your home tidy and avoid clutter. If possible, move small furniture items, such as side tables, to open up clear pathways to walk.
Use contrasting colors. Contrasting colors can help you find items more easily. For example, replace doorknobs and light switches with colors contrasting with the wall, and use a light cutting board to chop dark-colored food items.
Use audio devices. Many smart home devices now have talking features, which can be helpful if you have significant visual reduction. This includes, for example, setting alarms and reminders, locking and unlocking doors, and reading audiobooks.
Learn breathing exercises. Intentionally controlling your breath is a powerful tool to soothe your nervous system, which in turn helps with your vision. When you exhale for longer than you inhale, the vagus nerve — which runs from the neck all the way down to the diaphragm— sends a message to your brain to switch on your parasympathetic nervous system and deprioritize your sympathetic nervous system.
Get a second opinion. If you’ve only visited an optometrist and were told your eyes were fine, but you’re still experiencing post-COVID vision related symptoms, consider contacting a functional optometrist or neuro-ophthalmologist who specializes in functional vision evaluation and therapy.
Recover From Long COVID at Cognitive FX
Therapist demonstrates a treatment activity at Cognitive FX.
There aren’t many good healthcare options for those suffering from long COVID, but at Cognitive FX, we’ve seen an average of 60% symptom improvement after just one treatment week. Many of our patients experience improvement by the second day! We can provide more types of therapy at one time than other treatment providers. Your symptoms are real, they have a cause, and they can get better with appropriate treatment.
To determine if you are eligible for our treatment program, please schedule a consultation.
About Dr. Jaycie Loewen
Dr. Jaycie Loewen is a Clinical Neuroscientist who received her Doctorate of Neuroscience at the University of Utah. Her background includes the study of basic and clinical brain injury, including the publication of research regarding mechanisms of epilepsy pathophysiology. Her work has elucidated the role of glial and neuronal cell profiles in viral-induced brain injury and acute seizures. Dr. Loewen is further a Howard Hughes Medical Institute Scholar, with a Master's in Clinical Investigation awarded in 2018, as well as a recipient of the Higher Education Teaching Specialist Certificate. Through these degrees, she obtained experience with patient care and education as well as an understanding of the necessity of respecting patient experience and symptoms. Dr. Loewen’s focus is firstly patient care and education. She also provides literature analysis and aids in the publication of Cognitive FX’s research. Her goal is to improve Cognitive Fx’s ability to help patients through equal interaction and communication, as well as the furthering of concussion and mild traumatic brain injury treatment and science.
Apparently "some" still havent yet grasped the concept that the pps of a stock doesnt always mesh with its Intrinsic Value, which IMO applies to revive at this point.
The current share price has ZERO to do with the potential value of buccy if the fda simply approves the requested ep change.
Once that ?happens? all of this unhinged rhetoric about the current low pps should cease and some semblance of rational discourse returned.
Sorry but Im not falling for the ongoing game of "cat and mouse" being played between revive and the fda, along with the accompanying market shenanigans thats been a trading feature.......oh and mindless agitator(s) who have no clue about anything and a patently obvious agenda!
To those who have totally lost ALL confidence in the company..........by all means SELL since 5c or lower will be most welcome!!!
That has been been covered here in 1000s of pages of posts for 2.5 years already.
I suggest folks read the last 2.5 years of DD, research on research going back 32 years covering approved use of the drug, and save use of the drug for 32 years.
There are only 2 that I have any faith in right now, and $RVVTF is one, and is way more than just an antiviral, and that way more part is perfect for long haul autoimmune diseases which Long Haul Covid19 is..
I would say it it is one of two, and IMO, we already know it's long haul autoimmune success for 32 years for RA..
There is a lot less risk and lot more reward to buying here and now at these prices,
with 2.5 years of work behind us, and 2.5 years closer to the end game,
and the Long haul Covid story unfolding has added 10X to the possible value,
and smart money put millions of dollars weeks ago at .10/share in US Dollars
What are the odds that BP has hired hedge fund teams to drive the share price down so they can try to steal $RVVTF for chump change?
Only a fool sells this cheap, or hedge fund backed BP thief team
The only price I care about is the one I sell at, $3-$20/share, depending on what the baker delivers..
And the prices I buy more at...
Bingo!!!! "Ecomike this is the first time I've seen longcovid mentioned in $Rvvtf news...."
You go to the head of the glass. Congrats! Either MF figured this out, or read my posts.
Article here. https://psychedelicinvest.com/revive-therapeutics-provides-update-from-type-c-meeting-with-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/
This part .... The Company may also pursue additional studies with Bucillamine for Long COVID or COVID-related conditions, and various infectious and respiratory disorders should the data from the Study prove worthwhile.
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19:https://t.co/ikyyXRn9ur
— Psychedelic Invest (@psyinvest) March 9, 2023
Eco
Is this THE anti viral the market is looking for?
If true where’s the partnership
?
Doesn’t the ceo have an obligation to maximize shareholder value? Glad I wasn’t a sucker to but the overpriced offering
Never stated # 2. What I said if this was a blockbuster drug better to partner
Clearly it’s not a blockbuster drug. Not today atleast
It’s going to touch.05. Watch and learn
$RVVTF
25% of the world is finding out that Covid19 turned into Long haul Covid19, causing trillions of dollars/year in economic damage, with wide spread autoimmune symptoms mirroring
ME-CFS = Chronic fatigue Syndrome
EB-caused-MS Epstein Bars Caused Multiple Sclerosis
RA = Rheumatoid Arthritis
Lyme and Lupus...
All of which lead to other diseases, organ and joint damage, strokes and on and on...
All could helped by the use of RVVTF Bucillamine.
References:
https://www.theatlantic.com/science/archive/2022/03/epstein-barr-virus-mono-cancer-research/623881/
https://www.theguardian.com/science/2022/mar/20/can-we-vaccinate-against-epstein-barr-virus-multiple-sclerosis-cancer
:A recent example of this is in some cases of long Covid where the symptoms have been linked to reactivation of EBV, a mechanism that has also been proposed as a cause of chronic fatigue syndrome.
“It seems [color=red]clear that EBV reactivation could play a role in long-term consequences of Sars-CoV-2 infection[/color],” says Jeff Gold, a researcher at the World Organisation, which studies long Covid. “The family of symptoms for some long Covid patients is identical to those we would expect from the virus reactivating.”
"EBV is a puzzling pathogen that lies dormant in most of us. But its link to MS – detailed in a landmark new study – and some cancers has led to the development of new vaccines
In the 1970s, Hank Balfour, a virologist at the University of Minnesota Medical School, was studying the long-term survival prospects of kidney transplant patients when he noticed that a small proportion of them went on to develop a rare form of cancer known as post-transplant proliferative disorder.
He was particularly intrigued when he discovered that almost all of these patients had been infected with a virus called Epstein-Barr or EBV, a curious pathogen that has captivated and puzzled virus-hunters for decades.
“EBV can maintain latency within human cells,”"
_________
EBV is much like Covid19 apparently:
--------------------
"EBV has evolved to coexist with humanity for millions of years, long before the advent of modern humans. It has become adept in hiding in a type of immune cell called B cells, where it stays for decades. Because most of us catch EBV in childhood – more than half of children in England have contracted EBV by the age of 12 – we do not even realise we have it. The only noticeable time when EBV rears its head is when teenagers or young adults become infected or immune-suppressed and develop mononucleosis or glandular fever, an illness associated with extreme fatigue and swollen glands.
However, the presence of the virus in our bodies has also been associated with about 200,000 cases of cancer worldwide every year, which develop years after infection. Associations have been made between EBV and Hodgkin lymphoma, as well as cancers of the head, neck and stomach. In particular, it is estimated that about 40% of Hodgkin lymphoma cases in the UK are related to EBV infection, with those who have previously had glandular fever being at a higher risk. EBV has also been associated with a range of autoimmune disorders, from lupus to chronic fatigue syndrome."
We are sitting on a forking gold mine here people.
" The main problem is that EBV infection is ubiquitous – most estimates suggest that the virus is inside 95% of the world’s population. And because EBV-related cancers are relatively rare – fewer than one in 300 cancer cases in the UK, and about 1.5% of cancers globally, are connected to the virus – modern medicine has largely taken the approach of pretending that the problem does not exist.
“The problem with EBV is that clinicians don’t want to deal with it, because they don’t really know what to do with it,” says Balfour. “And academic researchers, for some reason, have shied away from EBV, perhaps because of its complexity.”"
"However, this may be about to change. In January, Science published a landmark study that showed overwhelmingly that EBV is implicated in multiple sclerosis (MS), an incurable autoimmune disease that affects the central nervous system.
Scientists, led by Alberto Ascherio from the Harvard TH Chan School of Public Health, examined more than 10m blood samples from US military personnel collected over 20 years and identified that those who became infected with EBV were 32 times more likely to later develop MS. Perhaps tellingly, the levels of a protein called neurofilament light chain – a marker in the blood that indicates nerve degeneration is occurring – increased only after EBV infection."
"A recent example of this is in some cases of long Covid where the symptoms have been linked to reactivation of EBV, a mechanism that has also been proposed as a cause of chronic fatigue syndrome. “It seems clear that EBV reactivation could play a role in long-term consequences of Sars-CoV-2 infection,” says Jeff Gold, a researcher at the World Organisation, which studies long Covid. “The family of symptoms for some long Covid patients is identical to those we would expect from the virus reactivating.”"
"Researchers are also interested in whether antiviral drugs that directly target EBV could provide ways of halting the progression of the disease in patients who already have MS. But while scientists have identified a number of candidates that can stop EBV replicating in a test tube, finding a drug that can clear the virus from the body remains a challenge."
Yes sounds great, but right now it's sitting at less then .08 cents. One can dream and I guess that's why my money is still here. GLTA
Ecomike this is the first time I've seen longcovid mentioned in $Rvvtf news....
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19:https://t.co/ikyyXRn9ur
— Psychedelic Invest (@psyinvest) March 9, 2023
People are way underestimating the value of $RVVTF Bucillamine, and how close $RVVTF is to $5.00/share moon shot rally on FDA approval.
For instance:
"The most prescribed antiviral for COVID-19 is Paxlovid. Many may not realize that Paxlovid was approved based on an 89% reduction in hospitalization over placebo."
Heads are going to spin when the $RVVTF data is exhumed from the completed trial.
No deaths, no ICUs, one went to hospital(?), the first 210 Placebos had a death and many ICUs,
I am fine with delays, done to insure an optimal outcome and approval... and to get the Long haul Covid option added to the meal..
Because the Long Haul Covid19 market could Make $RVVTF at $10 to $20/stock.
Source: https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses
Our service is fast no matter how long it takes.
The important thing is to get to the promised land.
The second important thing is to get there alive and kicking.
"
RVVTF only works on memory if there are brain cells left alive to Revive
Long Haul covid should be a shoo in for us...
LOLOL
I heard he was knocking on your front door with defamation lawsuit?
BS, if BP had a solution they would have already delivered it.
BP does not have sh*t.
$RVVTF does. $RVVTF has the real deal.. Bucillamine
Why do you think RVVTF was able to raise millions in cash weeks ago?
Lawsuits are common. 3M and DuPont are being sued for trillions of dollars for selling toxic PFAS-compounds used in firefighting foam and mud drops forest fires that are making all life on the planet sterile.
Only a fool sues themselves. Besides the FDA just hell yes, not no, to $RVVTF, so hats off to MF for the win for RVVTF shareholders.
But reading comprehension has become a lost art.
Yes pretty much have the same strategy for the same reason. LOL
You got that backwards sir. BP needs what RVVTF has bad, because Big Phama has screwed the pooch too many times and needs what RVVTF has very badly...
For all we know a BP partner is guiding MF on the FDA process....
So lets examine that BS story here:
Reading recent comments here makes me think Big Pharma wants to buy the $RVVTF Covid drug Bucci up fast, cheap and wants it now, bad enough to pay to drive the share price down and spook retail.
Its too obvious. I am adding to longs today.
Any one wants to sell, wants out, please sell now. Thanks
Current stack of rvv has been bought and paid for for quite some time now and profits long been put to good use.
Been utilizing this basic strategy since 2009/10 playing the Wamu bankruptcy and have been fine tuning it ever since.
Ready for more with this latest request, as expected, from the fda so no worries.
Been over this already but its become very obvious ye dont recall very well now do ye.
Think buccy is also great for issues re memory recall so do indulge. lololsss
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |